Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia (Q42545652)

2 November 2017

Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia (English)

1 reference

2 November 2017

0 references

1 reference

1 reference

Raal FJ

1

1 reference

2 November 2017

Pilcher GJ

2

1 reference

2 November 2017

Illingworth DR

3

1 reference

2 November 2017

Pappu AS

4

1 reference

2 November 2017

Stein EA

5

1 reference

2 November 2017

Laskarzewski P

6

1 reference

2 November 2017

Mitchel YB

7

1 reference

2 November 2017

Melino MR

8

1 reference

2 November 2017

1 December 1997

1 reference

2 November 2017

1 reference

2 November 2017

135

1 reference

2 November 2017

249-256

1 reference

2 November 2017

2

1 reference

A receptor-mediated pathway for cholesterol homeostasis

2 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

Advances in LDL-apheresis for the treatment of severe hypercholesterolemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

Increased urinary mevalonic acid excretion in patients with abetalipoproteinemia and homozygous hypobetalipoproteinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

The molecular basis and diagnosis of familial hypercholesterolaemia in South African Afrikaners

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

Two common low density lipoprotein receptor gene mutations cause familial hypercholesterolemia in Afrikaners

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

FH Afrikaner-3 LDL receptor mutation results in defective LDL receptors and causes a mild form of familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

Two mutant low-density-lipoprotein receptors in Afrikaners slowly processed to surface forms exhibiting rapid degradation or functional heterogeneity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

Molecular genetics of the LDL receptor gene in familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

Plasma lipoprotein distribution of apolipoprotein E in familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

Metabolic studies in familial hypercholesterolemia. Evidence for a gene-dosage effect in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

Regulation of the mevalonate pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900168-8

10.1016/S0021-9150(97)00168-8

7 January 2021

Identifiers

DOI

1 reference

2 November 2017

1 reference